Survanta Dosing Video

This video provides an overview of how to prepare and administer Survanta. Topics include: storage, dosing, product composition, rescue, prevention, and ventilation strategies; and re-treatment, observation, monitoring and procedures.

Important Safety Information about Survanta® (beractant)

SURVANTA is intended for intratracheal use only.

SURVANTA CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, its use should be restricted to a highly supervised clinical setting with immediate availability of clinicians experienced with intubation, ventilator management, and general care of premature infants. Infants receiving SURVANTA should be frequently monitored with arterial or transcutaneous measurement of systemic oxygen and carbon dioxide.

DURING THE DOSING PROCEDURE, TRANSIENT EPISODES OF BRADYCARDIA AND DECREASED OXYGEN SATURATION HAVE BEEN REPORTED. If these occur, stop the dosing procedure and initiate appropriate measures to alleviate the condition. After stabilization, resume the dosing procedure.

No information is available on the effects of doses other than 100 mg phospholipids/kg, more than 4 doses, dosing more frequently than every 6 hours, or administration after 48 hours of age.

Use of Survanta in infants less than 600 g birth weight has not been evaluated in controlled trials.

To learn more, see the Full Prescribing and Safety Information (Package Insert March 2009) for Survanta provided in Adobe Portable Document Format(PDF).